经导管动脉化疗栓塞术治疗原发性肝癌94例疗效观察

Clinical Observation on Treatment of 94 Cases of Primary Hepatocellular Carcinoma with Transcatheter Arterial Chemoembolization

目的观察经导管动脉化疗栓塞术(TACE)治疗原发性肝癌的疗效。方法观察94例原发性肝癌行TACE治疗的患者,随访其生存时间及生存质量,观察治疗前后肿瘤大小变化,分析TACE对于原发性肝癌的治疗效果。结果原发性肝癌患者TACE治疗后1年生存率为48.9%(46/94),2年生存率为24.6%,3年生存率为6.3%。首次TACE治疗后14d,外周血甲胎蛋白(AFP)下降率为49.4%。TACE治疗6个月,患者生活质量Karnofsky Performance Scale(KPS)评分好转率为17.07%,Quality of Life Sale (QOL)评分好转率为26.83%,Visual Analogue Scale (VAS)疼痛评分改善率为35.9%。但对于巨块型肝癌,1年生存率仅为3.2%,且TACE术后3个月,KPS评分恶化率为41.9%,QOL评分恶化率为35.5%。结论TACE用于治疗原发性肝癌可一定程度延长患者生存时间,并改善患者的生存质量,抑制癌细胞活动,但对巨块型肝癌效果有限。

Objective To observe the curative effect of transcatheter arterial chemoembolization(TACE)treatment for hepatocellular carcinoma(HCC).Methods Observed and fol ow-up visited the quality of live and the survival time,of 94 hepatocellular carcinoma patients that received TACE of 328 person-times,and monitored the change of tumor size before and after the treatment,then analyzed the curative effect of TACE for HCC.Results The surviva rate(SR)of HCC patients,after 1 year treatment of TACE,was 49.4%,and 2 years SR was 24.6%,and 3 years SR was 6.3%.After the first time TACE treatment,49.4%patients'alpha fetal protein(AFP)in peripheral blood were reduce.6 months after TACE treatment,the patients'survival quality,the Karnofsky Performance Scale(KPS)was 17.07%improved,and Quality of Life Sale(QOL)was 26.83%changed for the bet er,and Visual Analogue Scale(VAS)pain score was 35.9%alleviated.For the massive hepatocellular carcinoma especial y,the 1 year SR was 3.2%,and KPS was 41.9%deteriorate,together with QOL was 35.5%worsen after 3 months of TACE treatment.Conclusion It is useful,to a certain extent,to treat HCC with TACE,for extending the patients survival time,or improving their quality of life,or inhibiting their cancer cells activity.However,to treat massive HCC,TACE just have limited ef ects.